Acer Therapeutics and Opexa Therapeutics Sign Merger Agreement
Merger to create a pre-NDA-stage, NASDAQ-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet medical need Concurrent financing of $15.7 million from Acer investor syndicate Acer plans to file a NDA for its lead product, EDSIVO™, for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the first half of 2018 CAMBRIDGE, MA / THE WOODLANDS, TX /...
Read more









